SYS6043, a holding subsidiary of CSPC Innovation (300765.SZ), starts phase III clinical trial

Zhitongcaijing · 2d ago

Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Biology”), a holding subsidiary of the company, has recently launched a randomized, multi-center, open-label clinical trial evaluating SYS6043 compared the chemotherapies selected by researchers for platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants.

According to reports, SYS6043 (B7-H3 ADC) is an ADC product developed by Jushi Biotech that targets B7-H3, and its antibody part can specifically bind to the cell surface expressing B7-H3 and internalize it into cells; Linker-Drug (Linker-Drug) is a tetrapeptide ligand-conjugated topoisomerase I inhibitor, which can release small molecules of toxins to kill tumor cells through protease-specific shear, and exerts a bystander effect to kill surrounding tumor tissue cells without specificity. Unlike traditional wild-type crystallizable fragments (Fc), SYS6043 can reduce lymphocyte uptake and reduce the risk of off-target toxicity, thereby improving treatment safety.